AIM
LAB icon

ARK Investment Management’s Standard BioTools LAB Stock Holding History

ARK Investment Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,066,665
Closed -$3.93M – 196
2025
Q4 		$3.93M Buy
3,066,665
+44,937
+1% +$60.4K 0.03% 121
2025
Q3 		$3.93M Sell
3,021,728
-133,327
-4% -$175K 0.02% 127
2025
Q2 		$3.79M Sell
3,155,055
-297,835
-9% -$330K 0.03% 112
2025
Q1 		$3.73M Buy
3,452,890
+129,201
+4% +$181K 0.04% 113
2024
Q4 		$5.82M Sell
3,323,689
-5,626,076
-63% -$10.5M 0.05% 105
2024
Q3 		$17.3M Sell
8,949,765
-3,729,626
-29% -$7.3M 0.16% 69
2024
Q2 		$22.4M Sell
12,679,391
-363,049
-3% -$887K 0.2% 64
2024
Q1 		$35.3M Buy
+13,042,440
New +$31.5M 0.24% 60

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

ARK Investment Management's LAB Position: Q1 2026 in Review

ARK Investment Management sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 3,066,665 shares — an estimated $3.93M sold.

ARK Investment Management first reported a position in LAB in Q1 2024 and held it in 8 quarters. The position peaked at $35.3M in Q1 2024. 156 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • ARK Investment Management reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
  • ARK Investment Management sold 3,066,665 Standard BioTools shares in Q1 2026, an estimated $3.93M.
  • ARK Investment Management first reported a position in Standard BioTools in Q1 2024 and held it in 8 quarters.
  • ARK Investment Management's Standard BioTools position peaked at $35.3M in Q1 2024.
  • 156 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.